Pharmaceutical conglomerate Ipsen is set to be a beneficiary of Radius Health’s flotation, despite never investing money in the company, it has emerged. According to a source within Ipsen, Ipsen did not invest any cash in Radius directly, but took an equity share worth about 1% in Radius in lieu of a milestone payment worth…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
